|
1
|
Faust PL, Kornfeld S and Chirgwin JM:
Cloning and sequence analysis of cDNA for human cathepsin D. Proc
Natl Acad Sci USA. 82:4910–4914. 1985.
|
|
2
|
Barrett AJ and Cathepsin D: Purification
of isoenzymes from human and chicken liver. Biochem J. 117:601–607.
1970.
|
|
3
|
Têtu B, Brisson J, Côté C, et al:
Prognostic significance of cathepsin-D expression in node-positive
breast carcinoma: an immunohistochemical study. Int J Cancer.
55:429–435. 1993.
|
|
4
|
Veneroni S, Daidone MG, Di Fronzo C, et
al: Quantitative immunohistochemical determination of cathepsin-D
and its relation with other variables. Breast Cancer Res Treat.
26:7–13. 1993.
|
|
5
|
Métayé T, Millet C, Kraims JL, et al:
Estrogen receptors and cathepsin D in human thyroid tissue. Cancer.
72:1991–1996. 1993.
|
|
6
|
Warwas M and Taurowska E: Cathepsin D in
diagnosis of neoplastic diseases. Postepy Hig Med Dosw. 47:277–288.
1993.(In Polish).
|
|
7
|
Ferlay J, Shin HR, Bray F, et al: Cancer
Incidence and Mortality Worldwide: IARC CancerBase No. 10.
International Agency for Research on Cancer. GLOBOCAN; Lyon,
France: 2008, http://globocan.iarc.fr.
Accessed 4 July, 2010
|
|
8
|
Burger M, Catto JW, Dalbagni G, et al:
Epidemiology and risk factors of urothelial bladder cancer. Eur
Urol. 63:234–241. 2013.
|
|
9
|
Fernández-González A, Rychłowska J, Badía
R and Salzer R: SPR imaging as a tool for detecting mucin -
anti-mucin interaction. Outline of the development of a sensor for
near-patient testing for mucin. Microchim Acta. 158:219–225.
2007.
|
|
10
|
Lee HJ, Nedelkov D and Corn RM: Surface
plasmon resonance imaging measurements of antibody arrays for the
multiplexed detection of low molecular weight protein biomarkers.
Anal Chem. 78:6504–6510. 2006.
|
|
11
|
Gorodkiewicz E, Regulska E and
Roszkowska-Jakimiec W: Determination of the active form
concentration of cathepsins D and B by SPRI biosensors. J Lab
Diagn. 46:107–109. 2010.
|
|
12
|
Gorodkiewicz E and Regulska E: SPR imaging
biosensor for aspartyl cathepsins: sensor development and
application for biological material. Protein Pept Lett.
17:1148–1154. 2010.
|
|
13
|
Gorodkiewicz E, Regulska E and Wojtulewski
K: Development of an SPR imaging biosensor for determination of
cathepsin G in saliva and white blood cells. Mikrochim Acta.
173:407–413. 2011.
|
|
14
|
Gorodkiewicz E, Ostrowska H and Sankiewicz
A: SPR imaging biosensor for the 20S proteasome: sensor development
and application to measurement of proteasomes in human blood
plasma. Microchim Acta. 175:177–184. 2011.
|
|
15
|
Gorodkiewicz E, Charkiewicz R, Rakowska A,
et al: SPR imaging biosensor for podoplanin: sensor development and
application to biological materials. Microchim Acta. 176:337–343.
2012.
|
|
16
|
Gorodkiewicz E: Surface Plasmon Resonance
Imaging sensor for cathepsin determination based on immobilized
cystatin. Protein Pept Lett. 16:1379–1385. 2009.
|
|
17
|
Tokyol C, Köken T, Demirbas M, et al:
Expression of cathepsin D in bladder carcinoma: correlation with
pathological features and serum cystatin C levels. Tumori.
92:230–235. 2006.
|
|
18
|
Salman T, el-Ahmady O, el-Shafee M, et al:
Cathepsin-D and TNF-alpha in bladder cancer. Dis Markers.
12:253–259. 1996.
|
|
19
|
Kotaska K, Dusek P, Prusa R, et al: Urine
and serum cathepsin B concentration in the transitional cell
carcinoma of the bladder. J Clin Lab Anal. 26:61–65. 2012.
|
|
20
|
Szajda SD, Darewicz B, Kudelski J, et al:
Cancer procoagulant and cathepsin D activity in blood serum in
patients with bladder cancer. Pol Merkur Lekarski. 18(108):
651–653. 2005.
|
|
21
|
Herr HW: Transuretheral resection of
muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol.
19:89–93. 2001.
|
|
22
|
European Association of Urology.
Non-muscle-invasive (Ta, T1 and CIS) bladder cancer. http://www.uroweb.org/guidelines/online-guidelines/.
Accessed March 13, 2012
|
|
23
|
American Urological Association. Guideline
for the management of nonmuscle invasive bladder cancer: (stages
Ta, T1 and Tis): Update 2007. http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm.
Accessed November 15, 2007
|
|
24
|
Elissa S, Swellam M, Sadek M, et al:
Comparative evaluation of the nuclear matrix protein, fibronectin,
urinary bladder cancer antigen and voided urine cytology in the
detection of the bladder tumors. J Urol. 168:465–469. 2002.
|
|
25
|
Menéndez V, Fernández-Suárez A, Galán JA,
et al: Diagnosis of bladder cancer by analysis of urinary
fibronectin. Urology. 65:284–289. 2005.
|
|
26
|
Lotan Y, Shariat SF, Schmitz-Dräger BJ, et
al: Considerations on implementing diagnostic markers into clinical
decision making in bladder cancer. Urol Oncol. 28:441–448.
2010.
|
|
27
|
Catto JWF: Old and new urinary markers:
Which one is the PSA for bladder cancer? Eur Urol Suppl. 7:422–425.
2008.
|
